Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa‐foeto‐protein (AFP), neuron‐specific enolase (NSE) and CA19.9 from the NORIP study

Objective. Adhering to current IFCC recommendations, we calculated upper 97.5 % reference limits for serum tumor markers. Material and methods. Serum samples from 498 healthy individuals from the Nordic reference interval project (NORIP) were investigated for carcinoembryonic antigen (CEA), CA125 and MUC1 (episialin, CA15.3) using in‐house immunofluorometric assays and, for α‐foetoprotein (AFP), a PerkinElmer Life Sciences assay, neuron‐specific enolase (NSE) using an in‐house immunoradiometric assay and CA19.9 using a Beckman Access assay. All assays participate in external quality assessment programs. Results. CEA concentrations increased with age and smoking. Upper reference limits for non‐smokers were 3.59 µg/L at 50 years and 4.12 µg/L at 70 years. CA125 concentrations were age‐independent and the upper reference limit was 35.8 kU/L. MUC1 increased with age and body mass index (BMI). Upper reference limits were 31.7 kU/L at 40 years and BMI 24, 37.5 kU/L at 70 years and BMI 24, and 33.7 kU/L at 40 years and BMI 30. AFP increases with age, and the upper reference limits were 3.82 kU/L at 20 years and 8.70 kU/L at 60 years. An upper reference limit for NSE was 8.91 µg/L in non‐smokers; smokers exhibited significantly lower levels. The upper reference limit for individuals expressing CA19.9 was 28.3 kU/L. Conclusions. For AFP, CA125 and CA19.9, the reference levels obtained were close to previously reported reference ranges. Smoking and age were confirmed as covariates for CEA. The associations between MUC1 with age and BMI and between NSE and smoking have not been reported previously.

[1]  K. Nustad,et al.  Selection of monoclonal antibodies for use in an immunometric assay for carcinoembryonic antigen. , 1990, Journal of immunological methods.

[2]  O. Börmer.  Major disagreements between immunoassays of carcinoembryonic antigen may be caused by nonspecific cross-reacting antigen 2 (NCA-2). , 1991, Clinical chemistry.

[3]  N. Peat,et al.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. , 1990, The Journal of biological chemistry.

[4]  E. Hovig,et al.  BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case–control study , 2004, British Journal of Cancer.

[5]  P. S. Horn,et al.  Effect of outliers and nonhealthy individuals on reference interval estimation. , 2001, Clinical chemistry.

[6]  E. Paus,et al.  Expression and interconversion of neuron-specific enolase in patient sera and extracts from small-cell lung cancer cells. , 1996, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[7]  T. Lövgren,et al.  A new sensitive assay of human alpha-fetoprotein using time-resolved fluorescence and monoclonal antibodies. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[8]  E. Rose,et al.  Alpha-fetoprotein levels in normal adults. , 1992, The American journal of the medical sciences.

[9]  P. Chretien,et al.  Effect of age and cigarette smoking on carcinoembryonic antigen levels. , 1976, JAMA.

[10]  T. Ørntoft,et al.  Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. , 1999, Clinical chemistry.

[11]  H. E. Solberg,et al.  Approved recommendation (1987) on the theory of reference values. Part 6. Presentation of observed values related to reference values , 1987 .

[12]  D. Radice,et al.  Interchangeability of measurements of CA 19-9 in serum with four frequently used assays: an update , 2007, Clinical chemistry and laboratory medicine.

[13]  J. Kulpa,et al.  Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. , 2002, Clinical chemistry.

[14]  D Stamm,et al.  International Federation of Clinical Chemistry, Scientific Division: approved recommendation on the theory of reference values. Part 4. Control of analytical variation in the production, transfer and application of reference values. , 1991, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[15]  J. Bjerner,et al.  Age‐dependent biochemical quantities: An approach for calculating reference intervals , 2007, Scandinavian journal of clinical and laboratory investigation.

[16]  Callum G Fraser,et al.  Objective criteria for partitioning Gaussian-distributed reference values into subgroups. , 2002, Clinical chemistry.

[17]  Olle Nilsson,et al.  MUC1 Serum Assays in Breast Cancer: Tumor Specificities and Reference Levels , 2002, Tumor Biology.

[18]  O. Börmer.  A direct assay for carcinoembryonic antigen in serum and its diagnostic value in metastatic breast cancer. , 1982, Clinical biochemistry.

[19]  V. del Villar,et al.  Prevalence of abnormal levels of serum tumour markers in elderly people. , 1996, Age and ageing.

[20]  P. Rustad,et al.  Certificate of analysis NFKK Reference Serum X: a reprint , 2004, Scandinavian journal of clinical and laboratory investigation.

[21]  H E Solberg,et al.  International Federation of Clinical Chemistry (IFCC), Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values. Approved recommendation (1988) on the theory of reference values. Part 3. Preparation of individuals and collection of specimens for the production of reference , 1988, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[22]  C. Petitclerc,et al.  Approved recommendation (1987) on the theory of reference values. Part 2. Selection of individuals for the production of reference values , 1987 .

[23]  H E Solberg,et al.  International Federation of Clinical Chemistry (IFCC), Scientific Committee, Clinical Section, Expert Panel on Theory of Reference Values, and International Committee for Standardization in Haematology (ICSH), Standing Committee on Reference Values. Approved Recommendation (1986) on the theory of re , 1987, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[24]  M Nap,et al.  Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. , 1996, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[25]  H. E. Solberg.  Approved recommendation (1987) on the theory of reference values. Part 5. Statistical treatment of collected reference values. Determination of reference limits , 1987 .

[26]  P. Rustad,et al.  Nordic Reference Interval Project Bio‐bank and Database (NOBIDA): a source for future estimation and retrospective evaluation of reference intervals , 2004, Scandinavian journal of clinical and laboratory investigation.

[27]  P. Hyltoft Petersen,et al.  The Nordic Reference Interval Project 2000: recommended reference intervals for 25 common biochemical properties , 2004, Scandinavian journal of clinical and laboratory investigation.

[28]  F. Hirsch,et al.  Serum neuron specific enolase (S-NSE) reference interval evaluation by time-resolved immunofluorometry compared with a radioimmunoassay. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[29]  A. Lahti,et al.  Proposal for guidelines to establish common biological reference intervals in large geographical areas for biochemical quantities measured frequently in serum and plasma , 2004, Clinical chemistry and laboratory medicine.

[30]  M. Kuroki,et al.  Protein Epitopes in Carcinoembryonic Antigen , 2002, Tumor Biology.

[31]  E. Paus,et al.  A single-chain-Fv-based immunofluorometric assay specific for the CEA variant NCA-2. , 2003, Journal of immunological methods.

[32]  H E Solberg,et al.  Approved recommendation (1988) on the theory of reference values. Part 3. Preparation of individuals and collection of specimens for the production of reference values. , 1988, Clinica chimica acta; international journal of clinical chemistry.

[33]  I. Mackay,et al.  Increased carcinoembryonic antigen in heavy cigarette smokers. , 1973, Lancet.

[34]  D. Stanley.  Tietz Textbook of Clinical Chemistry , 1999 .

[35]  K. Nustad,et al.  Immunometric assay interference: incidence and prevention. , 2002, Clinical chemistry.

[36]  A. Neville,et al.  First British standard for carcinoembryonic antigen (CEA). , 1975, British Journal of Cancer.

[37]  R. Paxton,et al.  Antigenic sites in carcinoembryonic antigen. , 1989, Cancer research.

[38]  A. Lahti,et al.  Impact of subgroup prevalences on partitioning of Gaussian-distributed reference values. , 2002, Clinical chemistry.

[39]  K. Nustad,et al.  Immunoradiometric assay for alpha gamma- and gamma gamma-enolase (neuron-specific enolase), with use of monoclonal antibodies and magnetizable polymer particles. , 1989, Clinical chemistry.

[40]  H. E. Solberg,et al.  Approved recommendation (1986) on the theory of reference values. Part 1. The concept of reference values. , 1987 .